Treatment Outcomes of Patients with Ependymoma Receiving Radiotherapy: A Single Institution Experience
CONCLUSION: Incorporating radiotherapy into multimodal treatment has led to favorable outcomes in patients with ependymoma, and the extent of resection is a prognostic factor for the local control of intracranial ependymoma.PMID:38471461 | DOI:10.1159/000538321 (Source: Oncology)
Source: Oncology - March 12, 2024 Category: Cancer & Oncology Authors: Tiffany Ting-Fong Liu Jason Chia-Hsien Cheng Yu-Hsuan Chen Feng-Ming Hsu Keng-Hsueh Lan Chao-Yuan Huang Chun-Wei Wang Sung-Hsin Kuo Source Type: research
Comprehensive study of chromosomal CNVs and genomic variations predicting overall survival in Myelodysplastic syndromes
CONCLUSION: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients respectively with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.PMID:38442690 | DOI:10.1159/000536446 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Nehakumari Maurya Chandrakala Shanmukhaiah Somprakash Dhangar Manisha Madkaikar Babu Rao Vundinti Source Type: research
Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments
CONCLUSION: Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.PMID:38442691 | DOI:10.1159/000536541 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Matea Pavic Qiyu Li Stephanie Juritz Arunas Gircys Anita Wolfer Ulrich-Peter Rohr Source Type: research
Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment
CONCLUSIONS: The results indicate that the expression of SYNE1/Nesprin1 and SYNE1 mutations in patients with RCC are closely linked to their prognosis and responsiveness to sunitinib treatment.PMID:38442705 | DOI:10.1159/000536539 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Takafumi Fukushima Kohei Kobatake Kento Miura Kenshiro Takemoto Ryoken Yamanaka Ryo Tasaka Yuki Kohada Shunsuke Miyamoto Yohei Sekino Hiroyuki Kitano Keisuke Goto Kenichiro Ikeda Akihiro Goriki Keisuke Hieda Osamu Kaminuma Nobuyuki Hinata Source Type: research
Comprehensive study of chromosomal CNVs and genomic variations predicting overall survival in Myelodysplastic syndromes
CONCLUSION: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients respectively with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.PMID:38442690 | DOI:10.1159/000536446 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Nehakumari Maurya Chandrakala Shanmukhaiah Somprakash Dhangar Manisha Madkaikar Babu Rao Vundinti Source Type: research
Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments
CONCLUSION: Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.PMID:38442691 | DOI:10.1159/000536541 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Matea Pavic Qiyu Li Stephanie Juritz Arunas Gircys Anita Wolfer Ulrich-Peter Rohr Source Type: research
Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment
CONCLUSIONS: The results indicate that the expression of SYNE1/Nesprin1 and SYNE1 mutations in patients with RCC are closely linked to their prognosis and responsiveness to sunitinib treatment.PMID:38442705 | DOI:10.1159/000536539 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Takafumi Fukushima Kohei Kobatake Kento Miura Kenshiro Takemoto Ryoken Yamanaka Ryo Tasaka Yuki Kohada Shunsuke Miyamoto Yohei Sekino Hiroyuki Kitano Keisuke Goto Kenichiro Ikeda Akihiro Goriki Keisuke Hieda Osamu Kaminuma Nobuyuki Hinata Source Type: research
Comprehensive study of chromosomal CNVs and genomic variations predicting overall survival in Myelodysplastic syndromes
CONCLUSION: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients respectively with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.PMID:38442690 | DOI:10.1159/000536446 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Nehakumari Maurya Chandrakala Shanmukhaiah Somprakash Dhangar Manisha Madkaikar Babu Rao Vundinti Source Type: research
Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments
CONCLUSION: Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.PMID:38442691 | DOI:10.1159/000536541 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Matea Pavic Qiyu Li Stephanie Juritz Arunas Gircys Anita Wolfer Ulrich-Peter Rohr Source Type: research
Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment
CONCLUSIONS: The results indicate that the expression of SYNE1/Nesprin1 and SYNE1 mutations in patients with RCC are closely linked to their prognosis and responsiveness to sunitinib treatment.PMID:38442705 | DOI:10.1159/000536539 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Takafumi Fukushima Kohei Kobatake Kento Miura Kenshiro Takemoto Ryoken Yamanaka Ryo Tasaka Yuki Kohada Shunsuke Miyamoto Yohei Sekino Hiroyuki Kitano Keisuke Goto Kenichiro Ikeda Akihiro Goriki Keisuke Hieda Osamu Kaminuma Nobuyuki Hinata Source Type: research
Comprehensive study of chromosomal CNVs and genomic variations predicting overall survival in Myelodysplastic syndromes
CONCLUSION: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients respectively with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.PMID:38442690 | DOI:10.1159/000536446 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Nehakumari Maurya Chandrakala Shanmukhaiah Somprakash Dhangar Manisha Madkaikar Babu Rao Vundinti Source Type: research
Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments
CONCLUSION: Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.PMID:38442691 | DOI:10.1159/000536541 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Matea Pavic Qiyu Li Stephanie Juritz Arunas Gircys Anita Wolfer Ulrich-Peter Rohr Source Type: research
Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment
CONCLUSIONS: The results indicate that the expression of SYNE1/Nesprin1 and SYNE1 mutations in patients with RCC are closely linked to their prognosis and responsiveness to sunitinib treatment.PMID:38442705 | DOI:10.1159/000536539 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Takafumi Fukushima Kohei Kobatake Kento Miura Kenshiro Takemoto Ryoken Yamanaka Ryo Tasaka Yuki Kohada Shunsuke Miyamoto Yohei Sekino Hiroyuki Kitano Keisuke Goto Kenichiro Ikeda Akihiro Goriki Keisuke Hieda Osamu Kaminuma Nobuyuki Hinata Source Type: research
Comprehensive study of chromosomal CNVs and genomic variations predicting overall survival in Myelodysplastic syndromes
CONCLUSION: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients respectively with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.PMID:38442690 | DOI:10.1159/000536446 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Nehakumari Maurya Chandrakala Shanmukhaiah Somprakash Dhangar Manisha Madkaikar Babu Rao Vundinti Source Type: research
Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments
CONCLUSION: Approval and consensus decision rates at SMC in comparison to EMA and FDA were lower for (neo)adjuvant indications but not for advanced and metastastic NAS oncology indications.PMID:38442691 | DOI:10.1159/000536541 (Source: Oncology)
Source: Oncology - March 5, 2024 Category: Cancer & Oncology Authors: Matea Pavic Qiyu Li Stephanie Juritz Arunas Gircys Anita Wolfer Ulrich-Peter Rohr Source Type: research
